Inflammation triggers silent mutation to cause deadly lung disease
A simple viral infection in the lungs of rats can become a lethal form of pulmonary hypertension if a common mutation is present, new Stanford research shows.
Researchers at the Stanford University School of Medicine have found that inflammation in the lungs of rats, triggered by something as simple as the flu, may wake up a silent genetic defect that causes sudden onset cases of pulmonary hypertension, a deadly form of high blood pressure in the lungs.
“It’s a kind of one-two punch,” said Amy Tian, PhD, senior research scientist in pulmonary and critical care. “Basically, the first hit is the mutation, and the second hit is inflammation in the arteries of the lungs. You can be healthy and carrying this mutation, and all of the sudden you get a bacterial or viral infection, and it leads to this terrible disease. ”
Tian is the lead author of the study, which was published Aug. 29 in Circulation. Mark Nicolls, MD, professor and chief of pulmonary and critical care medicine, is the senior author.
“This is important research for understanding how ‘second hits’ can render ordinarily silent genetic mutations deadly,” Nicolls said.“It also further advances the the scientific understanding of the role of inflammation in pulmonary hypertension.”
There is no known cause of pulmonary hypertension, a debilitating disease that causes difficulty breathing, fatigue and chest pain. It can leave patients too weakened to perform simple daily activities, such as climbing a flight of stairs. About 200,000 people a year are hospitalized with the disease in the United States, according to the Pulmonary Hypertension Association of America. The only available cure for severe forms of the disease is lung transplantation, but it has only a 30% survival rate.
Weakening the heart
Pulmonary hypertension occurs when the arteries that transport blood from the heart to the lungs mysteriously thicken and become increasingly clogged, thereby weakening the heart, which has to pump extra hard to get blood to flow through the body. After diagnosis, most patients face a prognosis of just a few years of life before they die of heart failure. Some patients are born with the disease, but often it strikes in later life.
Treatment is limited to vasodilators, drugs that cause the smooth muscle cells of the diseased blood vessels in the lungs to relax, permitting more blood to flow through. These drugs help to extend survival and relieve some symptoms, but they are not a cure. Thus, scientists have been searching for other therapies.
Past research has shown that the majority of patients with the inherited form of pulmonary hypertension, which is also the most lethal, carry a mutation in the gene BMPR2. Whether the mutation plays a role in causing the disease has been unclear. Surprisingly, 80% of people with the mutation don’t get the disease and remain perfectly healthy, Nicolls said.
You can be healthy and carrying this mutation, and all of the sudden you get a bacterial or viral infection, and it leads to this terrible disease.
Based on previous research into inflammation in the lungs, the Stanford researchers hypothesized that an inflammation-producing pathway may provide the second “hit” that triggers the mutation to cause the disease in certain patients. To test the theory, the researchers developed a rat model with a mutation in the BMPR2 gene. They followed the rats for a year, and found that the animals remained healthy. Yet when the rats were injected with a virus carrying the 5LO enzyme that triggered temporary lung inflammation, they developed pulmonary hypertension.
“At first, the rats with this mutation were healthy, running around the cage,” Tian said. “Then after they received the virus, which stimulated the production of inflammation in the vessels of the lung, and they got really sick.”
The lung inflammation caused by the virus usually lasts only a few weeks and, in humans, can also be caused by environmental triggers, such as a severe flu or bacterial infection or even hiking to high altitudes. However, in the genetically susceptible rats, the virus led to permanent inflammation, damaging the lung vessels and causing a lethal form of pulmonary hypertension.
“Asthma, a bad flu, temporary types of lung injury from bacterial or virus infections — all can be 5LO-mediated,” Tian said. “This type of inflammation normally has a pretty short life span. But in these rats, even after the injected virus died, the damage to the endothelial cells in the lining of the blood vessels continued. The cells become the bad player, and they continued to proliferate the inflammation.”
These results indicate that limiting potential environmental causes of lung inflammation in patients with a genetic risk for pulmonary hypertension may help prevent the development of the disease, the study said.
Other Stanford co-authors of the study are Xinguo Jiang, MD, PhD, project leader; Yon Sung, MD, clinical assistant professor of pulmonary and critical care medicine; medical student Ting-Hsuan Wu; Peter Kao, MD, PhD, associate professor of pulmonary and critical care medicine; research scientists Aiqin Cao, PhD, and Lingli Wang, MD; research assistant Patrick Zhang; former postdoctoral scholar James Chappell, PhD; Shravani Pasupneti, MD, instructor of medicine; research assistants Petra Dahms, Allen Tu, Eric Shuffle and Yesl Kim; biostatician Peter Maguire; Hassan Chaib, PhD, director of laboratory operations; Roham Zamanian, MD, associate professor of medicine; Michael Snyder, MD, professor and chair of genetics; and Marlene Rabinovitch, MD, professor of pediatric cardiology.
Researchers at the University of Michigan, Virginia Commonwealth University, the Universite Paris-Sud and the Universite Paris-Saclay also contributed to the study.
This work was funded by the National Institutes of Health (grants HL014985, HL122887, HL138473, HL120001 and S0OD020141) and the Vera Moulton Wall Center.
Nicolls and Tian are co-inventors on a patent titled “Treatment of Pulmonary Hypertension with Leukotriene Inhibitors.”
Nicolls is a member of the Stanford Cardiovascular Institute.
The Stanford Department of Medicine also supported the work.
Stanford Medicine integrates research, medical education and health care at its three institutions - Stanford University School of Medicine, Stanford Health Care (formerly Stanford Hospital & Clinics), and Lucile Packard Children's Hospital Stanford. For more information, please visit the Office of Communication & Public Affairs site at http://mednews.stanford.edu.